ADARx Pharmaceuticals, Inc.

Co ADARx Pharmaceuticals, Inc. zaraportowała 12 listopada 2026

Z własnego raportu 8-K spółki.

Co powiedział zarząd

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline,”

Cytowane dosłownie z komunikatu i pokazywane tylko wtedy, gdy raport przypisuje wypowiedź konkretnej osobie.

Czym zajmuje się ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA (“siRNA”) therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx’s three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx’s goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

Własny opis spółki, tak jak widnieje na końcu komunikatu.